Natco Pharma Ltd. — Board/Management Information 2022

Sep 2, 2022

==> picture [432 x 45] intentionally omitted <==

2[nd] September 2022

Corporate Relationship Department The BSE Ltd. Dalal Street, Fort Mumbai 400 001 .

Manager – Listing M/s. National Stock Exchange of India Ltd “Exchange Plaza”, Bandra – Kurla Complex Bandra (E) Mumbai 400 051 .

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub: Outcome of Board meeting

We would like to inform you that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business:

1. To sell the investment of 15% of shareholding in Joint Limited Liability Company (JLLC) “Nativita”, a Company registered under the Companies Law of the Republic of Belarus for an amount of 3,45,000 (three lakh forty five thousand only) Euros to M/s. “Pharmasyntez-Nord” Joint Stock Company, a legal entity under the laws of the Russian Federation subject to the approval of the Statutory and Regulatory Authorities.

2. To assign the leasehold land wherein the Company’s Pharma Division is situated i.e., Plot No. 19 and Plot No. 18-A situated at Pharma City, SIIDCUL, Selaqui, Tehsil - Vikasnagar, Dehradun, Uttarakhand, India and sell the buildings, plant, machinery and fixtures constructed and/or installed in Plot No. 19 to M/s. Odon Lifesciences Private Limited for an amount of Rs.15.73 Crores (Rupees Fifteen Crores Seventy Three Lakhs only) which is subject to the approval of State Infrastructure and Industrial Development Corporation of Uttarakhand Limited (“SIIDCUL”), other Statutory and Regulatory Authorities.

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 is enclosed as Annexure – 1.

This is for your information and records.

Thanking you,

Yours faithfully,

For NATCO Pharma Limited

Chekuri Venkat Ramesh Digitally signed by Chekuri Venkat Ramesh DN: c=IN, st=Telangana, 2.5.4.20=90d42e387bd14ec84f24107c38bbe712c77d154e1e954b183b90527df9a5cf15, postalCode=500090, street=SHREE HOMES COLONY , BACHUPALLY , Bachpalle , Medchalmalkajgiri, pseudonym=6bb41d7c451b4872971cc058675f7c8c, serialNumber=f6910746a5f5b7b789b80a6f72d19727f6631efba3de76111828b13e92252ebc, o=Personal, cn=Chekuri Venkat Ramesh Date: 2022.09.02 12:33:42 +05'30'

Ch Venkat Ramesh Company Secretary & Compliance Officer

Encl: as above

Annexure- I

==> picture [432 x 45] intentionally omitted <==

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

(a)	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year;	Unit setup in 2005 contributed Rs.66.05 Crores (Rupees Sixty Six Crores Five Lakhs only) in turnover comprising 3.55% Standalone Turnover and Rs.11.84 Crores (Rupees Eleven Crores Eighty Four Lakhs only) net-worth comprising of 0.28% to the net-worth of the Company during the financial year 2021-22. There will be no impact on turnover and profitability, as these products are moved to the other Units of the Company
(b)	Date on which the agreement for sale has been entered into	NA
(c)	The expected date of completion of sale/disposal	6 months
(d)	Consideration received from such sale/disposal	₹ 15.73 crores (Book value is Rs.11.84 Crores)
(e)	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	M/s. Odon Lifesciences Private Limited CIN: U85190DL2021PTC387627 Buyer doesn’t belong to the Promoter/ Promotergroup/GroupCompanies
(f)	whether the transaction would fall within related party transactions? If yes, whether the same is done at “arms length”	No The transaction will not fall within related party transactions
(g)	additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slumpsale	NA